

TDMS No. 20009 - 04
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

beta-Picoline
CAS Number: 108-99-6

Date Report Requested: 05/27/2011
Time Report Requested: 09:52:35
First Dose M/F: 11/09/04 / 11/08/04
Lab: BAT

F2_M3

C Number: C20009
Lock Date: 05/05/2008
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.4.1.0_004
PWG Approval Date: 12/14/2010

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
------------------	--------	------------	----------	-----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	6	4	8	7
Natural Death	20	20	15	10
Survivors				
Terminal Sacrifice	24	26	27	33
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(36)	(33)	(39)	(42)
Degeneration, Hyaline		1 (3%)		
Inflammation, Chronic Active			1 (3%)	
Intestine Large, Cecum	(35)	(34)	(36)	(40)
Intestine Large, Colon	(40)	(40)	(41)	(40)
Intestine Large, Rectum	(39)	(38)	(42)	(41)
Intestine Small, Duodenum	(36)	(31)	(35)	(40)
Intestine Small, Ileum	(36)	(35)	(39)	(40)
Intestine Small, Jejunum	(35)	(32)	(37)	(40)
Diverticulum	1 (3%)			
Peyer's Patch, Hyperplasia, Lymphoid		1 (3%)		
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	3 (6%)	2 (4%)	3 (6%)
Basophilic Focus	10 (20%)	12 (24%)	15 (30%)	7 (14%)
Clear Cell Focus	15 (30%)	19 (38%)	16 (32%)	9 (18%)
Congestion				1 (2%)
Cyst				1 (2%)
Eosinophilic Focus	18 (36%)	16 (32%)	19 (38%)	10 (20%)
Fatty Change		1 (2%)		
Hematopoietic Cell Proliferation	1 (2%)			
Inflammation, Chronic			2 (4%)	1 (2%)
Inflammation, Chronic Active				2 (4%)
Mineralization			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Mixed Cell Focus	5 (10%)	4 (8%)	5 (10%)	4 (8%)
Necrosis	5 (10%)	6 (12%)	6 (12%)	4 (8%)
Mesentery	(7)	(1)	(1)	(1)
Inflammation, Chronic Active	1 (14%)			
Fat, Necrosis	5 (71%)		1 (100%)	1 (100%)
Pancreas	(49)	(48)	(48)	(49)
Atrophy	1 (2%)			
Necrosis				1 (2%)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(47)	(47)	(47)	(47)
Hyperplasia, Squamous	2 (4%)	4 (9%)	3 (6%)	1 (2%)
Ulcer	5 (11%)	3 (6%)	4 (9%)	1 (2%)
Stomach, Glandular	(42)	(45)	(43)	(45)
Mineralization		2 (4%)		
Necrosis			1 (2%)	
Ulcer	1 (2%)	2 (4%)		
Tooth	(35)	(41)	(42)	(41)
Dysplasia	35 (100%)	41 (100%)	42 (100%)	41 (100%)

CARDIOVASCULAR SYSTEM

Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	12 (24%)	17 (34%)	7 (14%)	4 (8%)
Inflammation, Suppurative	2 (4%)			
Mineralization	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Necrosis		1 (2%)	1 (2%)	
Thrombosis	2 (4%)	2 (4%)	1 (2%)	
Artery, Inflammation, Chronic Active			1 (2%)	2 (4%)

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(48)	(50)	(48)
Atrophy		1 (2%)		
Hyperplasia	10 (20%)	8 (17%)	10 (20%)	5 (10%)
Hypertrophy	12 (24%)	14 (29%)	14 (28%)	17 (35%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Subcapsular, Hyperplasia		1 (2%)		
Adrenal Medulla	(49)	(47)	(50)	(48)
Hyperplasia	1 (2%)	1 (2%)	1 (2%)	
Islets, Pancreatic	(49)	(48)	(48)	(49)
Hyperplasia		1 (2%)	2 (4%)	
Parathyroid Gland	(37)	(39)	(44)	(31)
Pituitary Gland	(47)	(49)	(49)	(49)
Thrombosis	1 (2%)			
Pars Distalis, Hyperplasia	1 (2%)		2 (4%)	
Thyroid Gland	(49)	(50)	(49)	(49)

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Coagulating Gland	(2)	(0)	(0)	(0)
Inflammation, Suppurative	1 (50%)			
Epididymis	(50)	(50)	(50)	(49)
Granuloma Sperm		1 (2%)		2 (4%)
Mineralization				1 (2%)
Preputial Gland	(50)	(50)	(50)	(50)
Cyst				1 (2%)
Inflammation, Chronic Active	3 (6%)	3 (6%)	4 (8%)	1 (2%)
Prostate	(50)	(50)	(48)	(50)
Hyperplasia		1 (2%)		
Inflammation, Suppurative	4 (8%)		2 (4%)	1 (2%)
Inflammation, Chronic Active			1 (2%)	
Seminal Vesicle	(47)	(48)	(49)	(47)
Amyloid Deposition			2 (4%)	1 (2%)
Inflammation, Suppurative	1 (2%)			
Inflammation, Chronic Active		1 (2%)	3 (6%)	2 (4%)
Testes	(50)	(50)	(50)	(50)
Atrophy	1 (2%)	2 (4%)	2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Mineralization Interstitial Cell, Hyperplasia		1 (2%)	1 (2%)	1 (2%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(48)	(50)
Angiectasis			1 (2%)	
Lymph Node	(2)	(1)	(0)	(2)
Renal, Hyperplasia, Lymphoid	1 (50%)			
Lymph Node, Mandibular	(50)	(49)	(49)	(50)
Infiltration Cellular, Plasma Cell			1 (2%)	
Lymph Node, Mesenteric	(45)	(45)	(43)	(45)
Hyperplasia, Lymphoid				1 (2%)
Inflammation, Chronic			1 (2%)	
Spleen	(46)	(48)	(47)	(46)
Hematopoietic Cell Proliferation	1 (2%)	1 (2%)		
Hyperplasia, Lymphoid	2 (4%)			
Thymus	(41)	(42)	(48)	(47)
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion	1 (2%)			
Inflammation, Chronic Active	2 (4%)	1 (2%)		
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Skeletal Muscle	(1)	(0)	(0)	(0)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Hemorrhage Glial Cell, Pigmentation	1 (2%)	1 (2%)		
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Hemorrhage	2 (4%)	1 (2%)		
Inflammation, Suppurative		1 (2%)		
Inflammation, Granulomatous	1 (2%)	1 (2%)		
Thrombosis			1 (2%)	2 (4%)
Alveolar Epithelium, Hyperplasia	4 (8%)	6 (12%)	6 (12%)	7 (14%)
Alveolus, Infiltration Cellular, Histiocyte	2 (4%)	1 (2%)	3 (6%)	2 (4%)
Bronchiole, Hyperplasia	1 (2%)		1 (2%)	
Nose	(50)	(50)	(50)	(50)
Inflammation, Suppurative	4 (8%)	9 (18%)	9 (18%)	6 (12%)
Olfactory Epithelium, Atrophy	3 (6%)	4 (8%)	8 (16%)	7 (14%)
Olfactory Epithelium, Metaplasia, Respiratory	8 (16%)	12 (24%)	30 (60%)	41 (82%)
Respiratory Epithelium, Hyperplasia	18 (36%)	23 (46%)	23 (46%)	17 (34%)
Pleura	(0)	(1)	(0)	(1)
Trachea	(47)	(49)	(45)	(49)
SPECIAL SENSES SYSTEM				
Eye	(36)	(39)	(43)	(40)
Degeneration	1 (3%)	1 (3%)	1 (2%)	1 (3%)
Inflammation, Suppurative				1 (3%)
Cornea, Inflammation, Chronic Active			1 (2%)	
Retina, Hemorrhage, Chronic	1 (3%)		1 (2%)	
Harderian Gland	(46)	(47)	(46)	(47)
Hyperplasia	1 (2%)	1 (2%)		4 (9%)
Inflammation, Chronic			1 (2%)	
URINARY SYSTEM				

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
Test Type: CHRONIC
Route: DOSED WATER
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
CAS Number: 108-99-6

Date Report Requested: 05/27/2011
Time Report Requested: 09:52:35
First Dose M/F: 11/09/04 / 11/08/04
Lab: BAT

B6C3F1 MICE MALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Kidney	(50)	(50)	(50)	(49)
Amyloid Deposition			1 (2%)	
Cyst	1 (2%)			
Hydronephrosis	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Infarct		1 (2%)	1 (2%)	
Inflammation, Suppurative	2 (4%)			1 (2%)
Metaplasia, Osseous	4 (8%)	4 (8%)	1 (2%)	4 (8%)
Mineralization	3 (6%)	2 (4%)	2 (4%)	1 (2%)
Nephropathy	43 (86%)	49 (98%)	49 (98%)	49 (100%)
Thrombosis	1 (2%)			
Artery, Inflammation, Chronic Active		1 (2%)	1 (2%)	
Papilla, Necrosis	2 (4%)		1 (2%)	2 (4%)
Renal Tubule, Hyperplasia			1 (2%)	
Renal Tubule, Hypertrophy		1 (2%)		
Renal Tubule, Pigmentation	1 (2%)			1 (2%)
Urethra	(3)	(3)	(5)	(3)
Inflammation, Suppurative	1 (33%)	3 (100%)	3 (60%)	1 (33%)
Urinary Bladder	(45)	(45)	(45)	(46)
Hemorrhage	1 (2%)	1 (2%)		
Inflammation, Suppurative	1 (2%)			
Inflammation, Chronic			1 (2%)	

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
--------------------	--------	------------	----------	-----------

Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	4	3	1	4
Natural Death	8	15	14	13
Survivors				
Natural Death			1	
Terminal Sacrifice	38	32	34	33
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(49)	(49)	(50)
Gallbladder	(43)	(36)	(36)	(35)
Degeneration, Hyaline			1 (3%)	1 (3%)
Intestine Large, Cecum	(44)	(36)	(38)	(39)
Intestine Large, Colon	(44)	(35)	(40)	(38)
Intestine Large, Rectum	(43)	(35)	(37)	(38)
Intestine Small, Duodenum	(42)	(35)	(36)	(37)
Lymphangiectasis			1 (3%)	
Intestine Small, Ileum	(44)	(36)	(37)	(37)
Inflammation, Acute			1 (3%)	
Intestine Small, Jejunum	(43)	(35)	(37)	(38)
Inflammation, Granulomatous		1 (3%)		
Inflammation, Acute			1 (3%)	
Liver	(49)	(50)	(50)	(50)
Angiectasis	3 (6%)	3 (6%)	6 (12%)	5 (10%)
Basophilic Focus	4 (8%)	2 (4%)	1 (2%)	6 (12%)
Clear Cell Focus	3 (6%)	2 (4%)	6 (12%)	
Congestion				1 (2%)
Eosinophilic Focus	11 (22%)	10 (20%)	14 (28%)	15 (30%)
Fatty Change		4 (8%)	1 (2%)	2 (4%)
Hematopoietic Cell Proliferation		1 (2%)		
Mixed Cell Focus				2 (4%)
Necrosis	4 (8%)	2 (4%)	3 (6%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Tension Lipidosis	1 (2%)	1 (2%)		2 (4%)
Thrombosis		1 (2%)		
Mesentery	(8)	(16)	(16)	(9)
Fat, Hemorrhage		1 (6%)		
Fat, Necrosis	7 (88%)	14 (88%)	13 (81%)	8 (89%)
Pancreas	(48)	(42)	(46)	(45)
Atrophy	2 (4%)		2 (4%)	1 (2%)
Thrombosis		1 (2%)		
Duct, Cyst	1 (2%)	1 (2%)		
Salivary Glands	(50)	(47)	(47)	(50)
Inflammation, Chronic				1 (2%)
Necrosis	1 (2%)			
Stomach, Forestomach	(47)	(43)	(45)	(47)
Hyperplasia, Squamous		1 (2%)	3 (7%)	3 (6%)
Ulcer		1 (2%)	1 (2%)	
Stomach, Glandular	(45)	(39)	(41)	(41)
Dysplasia			1 (2%)	
Hyperplasia		1 (3%)		
Mineralization	2 (4%)	2 (5%)	1 (2%)	
Tongue	(0)	(0)	(0)	(1)
Tooth	(0)	(1)	(2)	(9)
Dysplasia			2 (100%)	9 (100%)

CARDIOVASCULAR SYSTEM

Blood Vessel	(2)	(3)	(1)	(0)
Mineralization	2 (100%)	3 (100%)	1 (100%)	
Heart	(50)	(50)	(49)	(50)
Cardiomyopathy	4 (8%)	1 (2%)	7 (14%)	3 (6%)
Inflammation, Suppurative	1 (2%)	1 (2%)		1 (2%)
Mineralization	1 (2%)	4 (8%)	1 (2%)	
Necrosis		1 (2%)		
Thrombosis	2 (4%)	1 (2%)		
Artery, Inflammation, Chronic Active				1 (2%)
Capillary, Hyperplasia		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
--------------------	--------	------------	----------	-----------

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(45)	(46)	(50)
Hyperplasia	2 (4%)			1 (2%)
Hypertrophy	1 (2%)	1 (2%)		1 (2%)
Vacuolization Cytoplasmic			1 (2%)	
Adrenal Medulla	(49)	(45)	(46)	(50)
Hyperplasia		1 (2%)		
Islets, Pancreatic	(48)	(41)	(45)	(45)
Hyperplasia			1 (2%)	1 (2%)
Parathyroid Gland	(38)	(34)	(40)	(41)
Hyperplasia			2 (5%)	
Pituitary Gland	(50)	(46)	(47)	(46)
Pars Distalis, Angiectasis	3 (6%)	1 (2%)		1 (2%)
Pars Distalis, Hyperplasia	8 (16%)	14 (30%)	13 (28%)	7 (15%)
Thyroid Gland	(48)	(45)	(45)	(49)
Cyst				2 (4%)
Follicular Cell, Hyperplasia	1 (2%)			1 (2%)
Follicular Cell, Hypertrophy			1 (2%)	

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Clitoral Gland	(50)	(50)	(48)	(50)
Ovary	(49)	(48)	(48)	(47)
Cyst	5 (10%)	5 (10%)	5 (10%)	4 (9%)
Thrombosis			2 (4%)	4 (9%)
Uterus	(49)	(47)	(49)	(49)
Angiectasis		1 (2%)		
Inflammation, Acute				2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
Necrosis				1 (2%)
Thrombosis	1 (2%)		1 (2%)	
Endometrium, Hyperplasia, Cystic	33 (67%)	29 (62%)	33 (67%)	37 (76%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(49)	(46)	(48)	(49)
Angiectasis				1 (2%)
Lymph Node	(6)	(8)	(6)	(8)
Lumbar, Angiectasis	1 (17%)			
Lumbar, Hemorrhage			1 (17%)	
Mediastinal, Hyperplasia, Lymphoid	1 (17%)	1 (13%)		
Pancreatic, Ectasia	1 (17%)			
Renal, Ectasia	1 (17%)	1 (13%)	1 (17%)	
Lymph Node, Mandibular	(48)	(42)	(47)	(47)
Hyperplasia, Lymphoid			1 (2%)	
Lymph Node, Mesenteric	(46)	(38)	(45)	(46)
Angiectasis				1 (2%)
Hemorrhage			1 (2%)	1 (2%)
Spleen	(46)	(42)	(45)	(46)
Hematopoietic Cell Proliferation	4 (9%)	3 (7%)	5 (11%)	1 (2%)
Hyperplasia, Lymphoid				1 (2%)
Thrombosis		1 (2%)		
Thymus	(45)	(44)	(48)	(47)
Amyloid Deposition			1 (2%)	
Hyperplasia, Lymphoid			1 (2%)	1 (2%)

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(49)	(49)	(48)
Hyperplasia	1 (2%)			
Skin	(50)	(50)	(50)	(50)
Hyperplasia, Squamous		1 (2%)		
Inflammation, Acute			1 (2%)	
Inflammation, Chronic Active		2 (4%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Hyperostosis				1 (2%)
Skeletal Muscle	(1)	(0)	(0)	(1)
NERVOUS SYSTEM				
Brain	(50)	(47)	(47)	(50)
Hemorrhage		1 (2%)		1 (2%)
Necrosis		1 (2%)		
Peripheral Nerve	(1)	(0)	(0)	(1)
Spinal Cord	(1)	(0)	(0)	(1)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(49)	(50)
Hemorrhage				1 (2%)
Inflammation, Acute			1 (2%)	
Inflammation, Chronic Active		1 (2%)		
Mineralization	1 (2%)	3 (6%)	2 (4%)	
Alveolar Epithelium, Hyperplasia	2 (4%)	4 (8%)	3 (6%)	8 (16%)
Alveolus, Infiltration Cellular, Histiocyte	2 (4%)	1 (2%)	1 (2%)	
Bronchiole, Hyperplasia			3 (6%)	1 (2%)
Nose	(49)	(44)	(49)	(47)
Inflammation, Suppurative	1 (2%)			1 (2%)
Olfactory Epithelium, Atrophy	1 (2%)	2 (5%)	2 (4%)	7 (15%)
Olfactory Epithelium, Metaplasia, Respiratory	2 (4%)	2 (5%)	7 (14%)	14 (30%)
Respiratory Epithelium, Hyperplasia	7 (14%)	2 (5%)	6 (12%)	13 (28%)
Pleura	(0)	(0)	(0)	(1)
Trachea	(47)	(41)	(45)	(44)
Mineralization	1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20009 - 04
 Test Type: CHRONIC
 Route: DOSED WATER
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 beta-Picoline
 CAS Number: 108-99-6

Date Report Requested: 05/27/2011
 Time Report Requested: 09:52:35
 First Dose M/F: 11/09/04 / 11/08/04
 Lab: BAT

B6C3F1 MICE FEMALE	0 mg/l	312.5 mg/l	625 mg/l	1250 mg/l
SPECIAL SENSES SYSTEM				
Eye	(43)	(35)	(36)	(39)
Cataract	1 (2%)			
Degeneration	1 (2%)		1 (3%)	1 (3%)
Cornea, Inflammation, Acute	1 (2%)	1 (3%)		
Cornea, Inflammation, Chronic Active				1 (3%)
Harderian Gland	(45)	(41)	(43)	(47)
Hyperplasia	5 (11%)	2 (5%)	1 (2%)	1 (2%)
Inflammation, Chronic			1 (2%)	
Zymbal's Gland	(0)	(0)	(0)	(1)
URINARY SYSTEM				
Kidney	(49)	(47)	(48)	(49)
Amyloid Deposition	1 (2%)	1 (2%)	1 (2%)	
Hydronephrosis		1 (2%)		
Inflammation, Suppurative	1 (2%)			1 (2%)
Metaplasia, Osseous		1 (2%)	1 (2%)	
Mineralization	3 (6%)	2 (4%)	1 (2%)	2 (4%)
Nephropathy	29 (59%)	16 (34%)	25 (52%)	30 (61%)
Renal Tubule, Necrosis	2 (4%)	3 (6%)	1 (2%)	2 (4%)
Urinary Bladder	(44)	(37)	(39)	(41)
Inflammation, Chronic				1 (2%)

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion